Trial Outcomes & Findings for Treating Violence-related PTSD and Substance Risk in Low-income, Urban Adolescents (NCT NCT03737383)

Last Updated: 2026-05-15

Results Overview

assessed via PTSD checklist. The minimum score for this measure is 0 while the maximum is 80. Higher scores indicate more severe PTSD symptoms.

Recruitment status

COMPLETED

Study phase

Target enrollment

124 participants

Primary outcome timeframe

At baseline, at 1 month follow up, and at 3 month follow up

Results posted on

2026-05-15

Participant Flow

We recruited 50 participants for the phase 1 survey, 40 of them finished. We then recruited 74 participants into phase 2 and 60 completed the baseline (different participants than Phase 1). 1 Participant came back for the 1 month follow up. 9 participants came back for the 3 month follow up. 1 of them completed that follow up. The population this study used (homeless teens and young adults) made it extremely difficult to maintain contact so it was hard to follow up resulting in low numbers.

Participant milestones

Participant milestones
Measure	Feasibility and Preliminary Efficacy We will be administering Narrative Exposure Therapy to determine participant responses to the intervention, whether the intervention can be delivered successfully in this setting, and preliminary outcomes. Narrative Exposure Therapy: brief, trauma-focused treatment.
Phase 1 Baseline (One Time) STARTED	50
Phase 1 Baseline (One Time) COMPLETED	40
Phase 1 Baseline (One Time) NOT COMPLETED	10
Phase 2 Baseline STARTED	74
Phase 2 Baseline COMPLETED	60
Phase 2 Baseline NOT COMPLETED	14
1 Month Follow up STARTED	1
1 Month Follow up COMPLETED	1
1 Month Follow up NOT COMPLETED	0
3 Month Follow up STARTED	9
3 Month Follow up COMPLETED	1
3 Month Follow up NOT COMPLETED	8

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Feasibility and Preliminary Efficacy n=100 Participants We will be administering Narrative Exposure Therapy to determine participant responses to the intervention, whether the intervention can be delivered successfully in this setting, and preliminary outcomes. Narrative Exposure Therapy: brief, trauma-focused treatment.
Age, Categorical Baseline (Phase 1) · <=18 years	16 Participants n=40 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Age, Categorical Baseline (Phase 1) · Between 18 and 65 years	24 Participants n=40 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Age, Categorical Baseline (Phase 1) · >=65 years	0 Participants n=40 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Age, Categorical Baseline (Phase 2) · <=18 years	11 Participants n=60 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Age, Categorical Baseline (Phase 2) · Between 18 and 65 years	49 Participants n=60 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Age, Categorical Baseline (Phase 2) · >=65 years	0 Participants n=60 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Age, Continuous Baseline (phase 1 and phase 2)	18.95 years STANDARD_DEVIATION 2.51 • n=40 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Age, Continuous Baseline (phase 2)	19.66 years STANDARD_DEVIATION 2.35 • n=60 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Sex: Female, Male Baseline (Phase 1) · Female	20 Participants n=40 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Sex: Female, Male Baseline (Phase 1) · Male	20 Participants n=40 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Sex: Female, Male Baseline (Phase 2) · Female	16 Participants n=60 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Sex: Female, Male Baseline (Phase 2) · Male	44 Participants n=60 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Race (NIH/OMB) Baseline (Phase 1) · American Indian or Alaska Native	0 Participants n=40 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Race (NIH/OMB) Baseline (Phase 1) · Asian	0 Participants n=40 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Race (NIH/OMB) Baseline (Phase 1) · Native Hawaiian or Other Pacific Islander	1 Participants n=40 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Race (NIH/OMB) Baseline (Phase 1) · Black or African American	20 Participants n=40 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Race (NIH/OMB) Baseline (Phase 1) · White	9 Participants n=40 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Race (NIH/OMB) Baseline (Phase 1) · More than one race	7 Participants n=40 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Race (NIH/OMB) Baseline (Phase 1) · Unknown or Not Reported	3 Participants n=40 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Race (NIH/OMB) Baseline (Phase 2) · American Indian or Alaska Native	1 Participants n=60 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Race (NIH/OMB) Baseline (Phase 2) · Asian	0 Participants n=60 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Race (NIH/OMB) Baseline (Phase 2) · Native Hawaiian or Other Pacific Islander	1 Participants n=60 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Race (NIH/OMB) Baseline (Phase 2) · Black or African American	33 Participants n=60 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Race (NIH/OMB) Baseline (Phase 2) · White	14 Participants n=60 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Race (NIH/OMB) Baseline (Phase 2) · More than one race	6 Participants n=60 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Race (NIH/OMB) Baseline (Phase 2) · Unknown or Not Reported	5 Participants n=60 Participants • This is the baseline data from the two different phases of data collection. Together it adds up to the overall population.
Region of Enrollment United States	100 participants n=100 Participants

PRIMARY outcome

Timeframe: At baseline, at 1 month follow up, and at 3 month follow up

Population: This Outcome Measure was pre-specified to only be assessed in participants enrolled into Phase 2 and no data from Phase 1 participants was collected. Only 1 participant finished the follow up for 1 month and 3 month (they are a different participant).

assessed via PTSD checklist. The minimum score for this measure is 0 while the maximum is 80. Higher scores indicate more severe PTSD symptoms.

Outcome measures

Outcome measures
Measure	Feasibility and Preliminary Efficacy n=62 Participants We will be administering Narrative Exposure Therapy to determine participant responses to the intervention, whether the intervention can be delivered successfully in this setting, and preliminary outcomes. Narrative Exposure Therapy: brief, trauma-focused treatment.
Posttraumatic Stress Disorder Checklist-Civilian Version Baseline	31.45 score on a scale Standard Deviation 20.00
Posttraumatic Stress Disorder Checklist-Civilian Version 1 Month follow up	46 score on a scale Standard Deviation 0
Posttraumatic Stress Disorder Checklist-Civilian Version 3 month follow up	18 score on a scale Standard Deviation 0

SECONDARY outcome

Timeframe: Only 1 participant finished the follow up for 1 month and 3 month (they are a different participant).

Population: This Outcome Measure was pre-specified to only be assessed in participants enrolled into Phase 2 and no data from Phase 1 participants was collected. This measure was only reported on those who reported drinking

alcohol use assessed via AUDIT. The minimum score for this measure is 0 while the maximum is 40. Higher scores indicate more alcohol use.

Outcome measures

Outcome measures
Measure	Feasibility and Preliminary Efficacy n=62 Participants We will be administering Narrative Exposure Therapy to determine participant responses to the intervention, whether the intervention can be delivered successfully in this setting, and preliminary outcomes. Narrative Exposure Therapy: brief, trauma-focused treatment.
Alcohol Use Disorders Identification Test (AUDIT) Baseline	5.12 score on a scale Standard Deviation 7.05
Alcohol Use Disorders Identification Test (AUDIT) 1 month follow up	0 score on a scale Standard Deviation 0
Alcohol Use Disorders Identification Test (AUDIT) 3 month follow up	0 score on a scale Standard Deviation 0

SECONDARY outcome

Timeframe: Only 1 participant finished the follow up for 1 month and 3 month (they are a different participant).

alcohol consequences assessed via YAACQ. The minimum score for this measure is 0 while the maximum is 48. Higher scores indicate more alcohol consequences.

Outcome measures

Outcome measures
Measure	Feasibility and Preliminary Efficacy n=62 Participants We will be administering Narrative Exposure Therapy to determine participant responses to the intervention, whether the intervention can be delivered successfully in this setting, and preliminary outcomes. Narrative Exposure Therapy: brief, trauma-focused treatment.
Young Adult Alcohol Consequences Questionnaire (YAACQ) baseline	7.65 score on a scale Standard Deviation 9.90
Young Adult Alcohol Consequences Questionnaire (YAACQ) 1 month follow up	0 score on a scale Standard Deviation 0
Young Adult Alcohol Consequences Questionnaire (YAACQ) 3 month follow up	0 score on a scale Standard Deviation 0

Adverse Events

Questionnaire to Gather Data About Our Sample (Phase 1)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Feasibility and Preliminary Efficacy (Phase 2)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Jennifer Read

University at Buffalo

Phone: 716 645-0193

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place